David E. Lazar 13D and 13G filings for Cyclacel Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-08 10:52 am Sale | 2025-08-05 | 13D | Cyclacel Pharmaceuticals, Inc. CYCC | David E. Lazar | 0 0.000% | -129,629 (Position Closed) | Filing |
| 2025-08-04 7:24 pm Sale | 2025-07-30 | 13D | Cyclacel Pharmaceuticals, Inc. CYCC | David E. Lazar | 129,629 8.180% | -32,959 (-20.27%) | Filing |
| 2025-02-28 4:46 pm Purchase | 2025-02-06 | 13D | Cyclacel Pharmaceuticals, Inc. CYCC | David E. Lazar | 162,588 15.840% | 162,588 (New Position) | Filing |